Jane Huang
2022 - Prelude Therapeutics
In 2022, Jane Huang earned a total compensation of $2.9M as President and Chief Medical Officer at Prelude Therapeutics.
Compensation breakdown
| Bonus | $4,450 |
|---|---|
| Non-Equity Incentive Plan | $167,344 |
| Option Awards | $1,627,660 |
| Salary | $391,761 |
| Stock Awards | $729,000 |
| Total | $2,920,215 |
Huang received $1.6M in option awards, accounting for 56% of the total pay in 2022.
Huang also received $4.5K in bonus, $167.3K in non-equity incentive plan, $391.8K in salary and $729K in stock awards.
Rankings
In 2022, Jane Huang's compensation ranked 1,231st out of 5,506 executives tracked by ExecPay. In other words, Huang earned more than 77.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,231 out of 5,506 | 78th |
Division Manufacturing | 597 out of 2,985 | 80th |
Major group Chemicals And Allied Products | 217 out of 1,340 | 84th |
Industry group Drugs | 196 out of 1,243 | 84th |
Industry Pharmaceutical Preparations | 144 out of 897 | 84th |
Source: SEC filing on April 28, 2023.
Huang's colleagues
We found two more compensation records of executives who worked with Jane Huang at Prelude Therapeutics in 2022.
News
Prelude Therapeutics CEO Krishna Vaddi's 2023 pay slips 20% to $2.6M
April 26, 2024
Prelude Therapeutics CEO Krishna Vaddi's 2022 pay falls 53% to $3.3M
April 28, 2023
BeiGene, Ltd. CEO John Oyler's 2019 pay falls 55% to $13M
April 28, 2020
BeiGene, Ltd. CEO John Oyler's 2018 pay jumps 171% to $28M
April 29, 2019